Comparison between Influx Healthtech IPO and Mahamaya Lifesciences IPO.
Influx Healthtech IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Mahamaya Lifesciences IPO is a SME Bookbuilding proposed to list at BSE SME.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Rarever Financial Advisors Pvt.Ltd. | Oneview Corporate Advisors Pvt.Ltd. |
| Registrar | Maashitla Securities Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | R.K.Stock Holding Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Influx Healthtech IPO is up to ₹55.63 Cr whereas the issue size of the Mahamaya Lifesciences IPO is up to ₹0.00 Cr. The final issue price of Influx Healthtech IPO is ₹96.00 per share and of Mahamaya Lifesciences IPO is .
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹91.00 per share | |
| Issue Price (Upper) | ₹96.00 per share | |
| Issue Price (Final) | ₹96.00 per share | |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 1200 shares | |
| Fresh Issue Size | 46,94,400 shares | 56,38,800 shares |
| Fresh Issue Size (Amount) | up to ₹45.07 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 11,00,400 shares | 5,40,000 shares |
| OFS Issue Size (Amount) | up to ₹10.56 Cr | up to ₹0.00 Cr |
| Issue Size Total | 57,94,800 shares | 61,78,800 shares |
| Issue Size Total (Amount) | up to ₹55.63 Cr | up to ₹0.00 Cr |
Influx Healthtech IPO opens on Jun 18, 2025, while Mahamaya Lifesciences IPO opens on . The closing date of Influx Healthtech IPO and Mahamaya Lifesciences IPO is Jun 20, 2025, and , respectively.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| Anchor Bid Date | Jun 17, 2025 | |
| Issue Open | Jun 18, 2025 | |
| Issue Close | Jun 20, 2025 | |
| Basis Of Allotment (Tentative) | Jun 23, 2025 | |
| Initiation of Refunds (Tentative) | Jun 24, 2025 | |
| Credit of Share (Tentative) | Jun 24, 2025 | |
| Listing date (Tentative) | Jun 25, 2025 | |
| Anchor Lockin End date 1 | Jul 23, 2025 | |
| Anchor Lockin End date 2 | Sep 21, 2025 |
Influx Healthtech IPO P/E ratio is 13.04, as compared to Mahamaya Lifesciences IPO P/E ratio of .
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Influx Healthtech Limited Financial Information (Restated)Influx Healthtech Limited's revenue increased by 5% and profit after tax (PAT) rose by 19% between the financial year ending with March 31, 2025 and March 31, 2024.
| Mahamaya Lifesciences Limited Financial Information (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.85 | 77.27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.53 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 13.04 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹222.24 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 36.98% | 23.67% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 49.17% | 32.38% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 36.98% | 21.16% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Influx Healthtech IPO Retail Individual Investors (RII) are offered 20,29,200 shares while in Mahamaya Lifesciences IPO retail investors are offered 20,29,200 shares. Qualified Institutional Buyers (QIB) are offered 11,59,200 shares in Influx Healthtech IPO and in Mahamaya Lifesciences IPO.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| Anchor Investor Reserveration | 17,36,400 shares | |
| Market Maker Reserveration | 3,06,000 shares | |
| QIB | 11,59,200 shares | |
| NII | 8,70,000 shares | |
| RII | 20,29,200 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 57,94,800 shares |
Influx Healthtech IPO subscribed 201.35x in total, whereas Mahamaya Lifesciences IPO subscribed .
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| QIB (times) | 137.87x | |
| NII (times) | 481.10x | |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 117.68x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 201.35x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
